MicroRNA 150-5p Improves Risk Classification for Mortality within 90 Days after Acute Ischemic Stroke
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose Micro ribonucleic acid-150-5p (miR-150-5p) regulates proinflammatory cytokines as well as vessel integrity. We evaluated the incremental prognostic value of logarithm (log) of miR-150-5p plasma levels after ischemic stroke. Methods In a prospective cohort study, levels of miR-150-5p were measured within 72 hours of symptom onset in 329 ischemic stroke patients. The outcome measures were unfavorable functional outcome (assessed by the modified Rankin Scale score >2) and mortality within 90 days. Logistic regression and Cox proportional hazards models were fitted to estimate odds ratio (OR), respectively hazard ratio (HR) and 95% confidence interval (CI) for the association between log-miR-150-5p and the outcome measures. The discriminatory accuracy was assessed with the area under the receiver-operating-characteristic curve (AUC) and the incremental prognostic value was estimated with the net reclassification index. Results After adjusting for demographic and vascular risk factors, lower log-miR-150-5p levels were independently associated with mortality (HR 0.21 [95% CI, 0.08–0.51], P=0.001) but not functional outcome (OR 1.10 [95% CI, 0.54–2.25], P=0.79). Adding log-miR-150-5p improved the discriminatory accuracy of the best multivariate model to predict mortality from an AUC of 0.91 (95% CI, 0.88–0.95) to 0.92 (95% CI, 0.88–0.96 Likelihood-ratio test-P<0.001), and resulted in a net reclassification index of 37.3% (95% CI, 0.28–0.52). Conclusions In patients with ischemic stroke, log-miR-150-5p is a novel prognostic biomarker, highly associated with mortality within 90 days, improving risk classification beyond traditional risk factors.
Abstract
Background and Purpose Micro ribonucleic acid-150-5p (miR-150-5p) regulates proinflammatory cytokines as well as vessel integrity. We evaluated the incremental prognostic value of logarithm (log) of miR-150-5p plasma levels after ischemic stroke. Methods In a prospective cohort study, levels of miR-150-5p were measured within 72 hours of symptom onset in 329 ischemic stroke patients. The outcome measures were unfavorable functional outcome (assessed by the modified Rankin Scale score >2) and mortality within 90 days. Logistic regression and Cox proportional hazards models were fitted to estimate odds ratio (OR), respectively hazard ratio (HR) and 95% confidence interval (CI) for the association between log-miR-150-5p and the outcome measures. The discriminatory accuracy was assessed with the area under the receiver-operating-characteristic curve (AUC) and the incremental prognostic value was estimated with the net reclassification index. Results After adjusting for demographic and vascular risk factors, lower log-miR-150-5p levels were independently associated with mortality (HR 0.21 [95% CI, 0.08–0.51], P=0.001) but not functional outcome (OR 1.10 [95% CI, 0.54–2.25], P=0.79). Adding log-miR-150-5p improved the discriminatory accuracy of the best multivariate model to predict mortality from an AUC of 0.91 (95% CI, 0.88–0.95) to 0.92 (95% CI, 0.88–0.96 Likelihood-ratio test-P<0.001), and resulted in a net reclassification index of 37.3% (95% CI, 0.28–0.52). Conclusions In patients with ischemic stroke, log-miR-150-5p is a novel prognostic biomarker, highly associated with mortality within 90 days, improving risk classification beyond traditional risk factors.
참고문헌 (31)
- Ntaios G, "An integer-based score to predict functional outcome in acute ischemic stroke: the ASTRAL score", Neurology, 78, pp.1916~1922 (2012)
- Saposnik G, "IScore: a risk score to predict death early after hospitalization for an acute ischemic stroke", Circulation, 123, pp.739~749 (2011)
- Whiteley W, "Blood biomarkers in the diagnosis of ischemic stroke: a systematic review", Stroke, 39, pp.2902~2909 (2008)
- Whiteley W, "Blood markers for the prognosis of ischemic stroke: a systematic review", Stroke, 40, pp.e380~e389 (2009)
- De Marchis GM, "Copeptin adds prognostic information after ischemic stroke: results from the CoRisk study", Neurology, 80, pp.1278~1286 (2013)
- Salic K, "MicroRNAs as biomarkers for myocardial infarction", Curr Atheroscler Rep, 14, pp.193~200 (2012)
- Gilad S, "Serum microRNAs are promising novel biomarkers", PLoS One, 3, pp.e3148~ (2008)
- Devaux Y, "MicroRNA-150: a novel marker of left ventricular remodeling after acute myocardial infarction", Circ Cardiovasc Genet, 6, pp.290~298 (2013)
- Liu Z, "MicroRNA-150 protects the heart from injury by inhibiting monocyte accumulation in a mouse model of acute myocardial infarction", Circ Cardiovasc Genet, 8, pp.11~20 (2015)
- Zhang Y, "Secreted monocytic miR-150 enhances targeted endothelial cell migration", Mol Cell, 39, pp.133~144 (2010)
- He QW, "MiR-150regulates poststroke cerebral angiogenesis via vascular endothelial growth factor in rats", CNS Neurosci Ther, 22, pp.507~517 (2016)
- Katan M, "Copeptin: a novel, independent prognostic marker in patients with ischemic stroke", Ann Neurol, 66, pp.799~808 (2009)
- Waltimo O, "Outcome of stroke in the Espoo--Kauniainen area, Finland", Ann Clin Res, 12, pp.326~330 (1980)
- Brott T, "Measurements of acute cerebral infarction: a clinical examination scale", Stroke, 20, pp.864~870 (1989)
- Adams HP Jr, "Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment", Stroke, 24, pp.35~41 (1993)
- Devaux Y, "Use of circulating microRNAs to diagnose acute myocardial infarction", Clin Chem, 58, pp.559~567 (2012)
- Devaux Y, "Association of circulating microRNA-124-3p levels with outcomes after out-of-hospital cardiac arrest: a substudy of a randomized clinical trial", JAMA Cardiol, 1, pp.305~313 (2016)
- Sims JR, "ABC", 2 for rapid clinical estimate of infarct, perfusion, and mismatch volumes, 2009, pp.72, 2104~2110
- Li P, "Multiple imputation: a flexible tool for handling missing data", JAMA, 314, pp.1966~1967 (2015)
- White IR, "Multiple imputation using chained equations: issues and guidance for practice", Stat Med, 30, pp.377~399 (2011)
- Pencina MJ, "Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers", Stat Med, 30, pp.11~21 (2011)
- Rolland-Turner M, "Adenosine stimulates the migration of human endothelial progenitor cells. Role of CXCR4 and microRNA-150", PLoS One, 8, pp.e54135~ (2013)
- Goren Y, "Relation of reduced expression of MiR-150 in platelets to atrial fibrillation in patients with chronic systolic heart failure", Am J Cardiol, 113, pp.976~981 (2014)
- Fleissner F, "Short communication: asymmetric dimethylarginine impairs angiogenic progenitor cell function in patients with coronary artery disease through a microRNA-21-dependent mechanism", Circ Res, 107, pp.138~143 (2010)
- Xiao C, "MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb", Cell, 131, pp.146~159 (2007)
- Vasilescu C, "MicroRNA fingerprints identify miR-150 as a plasma prognostic marker in patients with sepsis", PLoS One, 4, pp.e7405~ (2009)
- Roderburg C, "Circulating microRNA-150 serum levels predict survival in patients with critical illness and sepsis", PLoS One, 8, pp.e54612~ (2013)
- Rhodes CJ, "Reduced microRNA-150 is associated with poor survival in pulmonary arterial hypertension", Am J Respir Crit Care Med, 187, pp.294~302 (2013)
- Choi GH, "Association of miR-34a, miR-130a, miR-150 and miR-155 polymorphisms with the risk of ischemic stroke", Int J Mol Med, 38, pp.345~356 (2016)
- Hlatky MA, "Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association", Circulation, 119, pp.2408~2416 (2009)
- Vickers AJ, "One statistical test is sufficient for assessing new predictive markers", BMC Med Res Methodol, 11, pp.13~ (2011)